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ABSTRACT
Epidermal growth factor receptor (EGFR) is an oncogenic receptor tyrosine 
kinase. Canonically, the tyrosine kinase activity of EGFR is regulated by its 
extracellular ligands. However, ligand-independent activation of EGFR exists in 
certain cancer cells, and the underlying mechanism remains to be defined. In this 
study, using PC3 and A549 cells as a model, we have found that, in the absence 
of extracellular ligands, a subpopulation of EGFR is constitutively active, which is 
needed for maintaining cell proliferation. Furthermore, we have found that fatty acid 
synthase (FASN)-dependent palmitoylation of EGFR is required for EGFR dimerization 
and kinase activation. Inhibition of FASN or palmitoyl acyltransferases reduced the 
activity and down-regulated the levels of EGFR, and sensitized cancer cells to EGFR 
tyrosine kinase inhibitors. It is concluded that EGFR can be activated intracellularly 
by FASN-dependent palmitoylation. This mechanism may serve as a new target for 
improving EGFR-based cancer therapy.
INTRODUCTION
Epidermal growth factor receptor (EGFR) is a member 
of the epidermal growth factor receptor tyrosine kinase 
family (ErbB family) that includes four members, EGFR 
(HER1), HER2/Neu, HER3 and HER4. EGFR is frequently 
overexpressed in many human cancers and correlates with 
cancer progression, metastasis, and poor prognosis [1]. 
Structurally, EGFR is compartmentalized into three major 
domains; an extra cellular domain (ECD), a trans-membrane 
domain (TMD) and an intra-cellular domain (ICD). 
The ECD has a ligand binding domain (LBD); the TMD 
consists of 23 amino acids and anchors EGFR to the plasma 
membrane; and the ICD consists of the tyrosine kinase 
domain and a tyrosine rich domain that transduces signals 
to its downstream pathways such as the PI3K/Akt. Upon 
binding to its ligand, EGFR undergoes homo- or  hetero-
dimerization with another ErbB member. Dimerization of 
the receptor induces intermolecular auto-phosphorylation of 
EGFR which in turn initiates the activation of downstream 
signaling cascades. EGFR-targeted therapies have been 
developed based on the understanding of ligand-dependent 
and kinase-dependent functions of EGFR. Available anti-
EGFR agents include EGFR monoclonal antibodies that 
prevent EGFR from binding to its extracellular ligands and 
small molecule tyrosine kinase inhibitors (TKIs) that block 
the tyrosine kinase domain in EGFR by competing with ATP 
[2]. However, interfering with EGFR signaling by these anti-
EGFR reagents has produced limited effects at the clinic [3]. 
For example, inhibition of the tyrosine kinase of EGFR by 
TKIs has produced responding rates range between 10–20% 
in lung cancer patients; however, all patients acquired 
resistance within few months after treatment,[4, 5] and 
prostate cancer, a type of cancer where EGFR is commonly 
overexpressed, is innately resistant to EGFR TKIs [6, 7].
In cancer cells, EGFR and its downstream pathways 
can be constitutively activated independent of external 
signals [8, 9]. Overexpression of EGFR instantly leads 
to constitutive activation of EGFR in the absence of 
ligands [8]. The EGFR vIII, which lacks the ability 
of ligand binding, is overexpressed and constitutively 
active in cancer cells of glioblastoma multiforme [10]. 
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Similarly, enhanced EGFR constitutive activation was 
observed in EGFR mutants with amino acid substitutions 
in the tyrosine kinase domain [11, 12]. The ligand-
independent activation of EGFR suggests that EGFR can 
be activated intracellularly. In support of this possibility, 
studies have shown that EGFR can be dimerized 
independent of ligands, [13] and EGFR can be activated 
by fatty acid synthase (FASN) [14]. However, the 
intracellular mechanism by which EGFR is dimerized and 
activated independent of extracellular ligand remains to be 
defined. FASN-dependent protein palmitoylation regulates 
protein functions [15–19]. Previously, we have reported 
that EGFR physically interacts with FASN,[15] which led 
us to hypothesize that de novo synthesized palmitate by 
FASN may affect the activity of EGFR by palmitoylation.
In this study, using PC3 (prostate cancer) and A549 
(lung cancer) cells, we explored the mechanism underlying 
EGFR’s ligand-independent activation. We’ve found that 
FASN-dependent palmitoylation of EGFR is critical for 
both EGFR’s ligand-independent and ligand-dependent 
dimerization and activation, and targeting this pathway 
potentiated the growth inhibitory effect of EGFR TKIs.
RESULTS
Ligand-independent constitutive activation of 
EGFR sustains the growth of cancer cells
Constitutive activation of EGFR in cancer cells 
in the absence of extracellular ligands (under serum 
free conditions) is well known; however, it is not clear 
regarding whether this activation of EGFR is sustained by 
extracellular or intrinsic signals. To address this question, 
we first examined the constitutive activity of EGFR in 
several cancer cell lines (PC3, DU145, A549, and HT29) 
cultured in serum free medium for 24 hrs. Constitutively 
active EGFR was detected in all of these cells (Figure 1a). 
We then chose two cell lines, PC3 and A549, for further 
investigations. Cross linking experiments revealed that 
EGFR constitutive activity was specifically associated 
with the dimerized form of EGFR (Figure 1b) in the 
absence of external ligands. To determine whether the 
EGFR constitutive activity is sustained by ligands present 
in the serum free medium, we added Cetuximab (C225), 
an antibody that blocks EGFR from binding to its ligand, 
into the serum free medium. As shown in Figure 1c, C225 
effectively blocked EGF-induced EGFR activation but 
failed to inhibit the constitutive activation of EGFR. In 
contrast to C225, AEE788, a small molecule of EGFR 
tyrosine kinase inhibitor (TKI), completely blocked both 
the EGF-induced and the constitutive activation of EGFR 
(Figure 1d), suggesting that EGFR constitutive activity 
in the absence of serum is not mediated by extracellular 
ligands and might be sustained by intracellular signaling. 
Ligand-independent activation is well characterized 
for EGFR vIII, an EGFR mutant that does not bind to 
ligands due to the lack of part of the LBD. To further 
determine the role of intracellular signaling in activating 
EGFR, we created an EGFR mutant that lacks the entire 
extracellular domain (∆ECD-EGFR) and transfected it 
into HEK293 cells in the absence of serum. As shown 
in Figure 1e and 1f, both the full length EGFR and the 
∆ECD-EGFR could be phosphorylated, further supporting 
that EGFR can be activated independent of external 
ligands. To test the significance of this ligand-independent 
constitutive activity of EGFR on Akt and ERK signaling, 
we treated A549 with C225 or AEE788 in the absence 
of serum. As shown in Figure 1g, C225 blocked EGF-
induced Akt and ERK phosphorylation but failed to 
block their basal activities, whereas AEE788 completely 
blocked both EGF-induced and basal activities of Akt and 
ERK. These results suggest that the ligand-independent 
constitutive activity of EGFR is required to sustain its 
downstream signaling pathways such as Akt and ERK. To 
further determine whether the ligand-independent EGFR 
activation is involved in sustaining cell proliferation in the 
absence of serum, we treated A549 cells with increasing 
concentration of AEE788 or C225 and measured their 
effects on cell growth. As shown in Figure 1h, AEE788 
treatment significantly inhibited cell proliferation in a 
dose dependent manner, whereas C225 failed to repress 
cell proliferation. Consistent with the cell proliferation 
data, AEE788 reduced colony formation of A549 and PC3 
cells in a dose dependent manner and C225 failed to show 
any effect on colony formation of these cells (Figure 1i 
and Suppl Figure 1). Together, these results suggest 
that ligand-independent intracellular signal dependent 
constitutive activation of EGFR sustains cell proliferation 
in the absence of external ligands.
Constitutive activation and ligand-induced 
activation of EGFR are mediated by de novo 
fatty acid synthesis dependent palmitoylation
It has been shown that de novo fatty acid synthesis 
is involved in the activation of EGFR and HER2 [14, 
15]. To determine whether de novo fatty acid synthesis 
is involved in the constitutive activation of EGFR, we 
inhibited FASN using an FASN inhibitor, cerulenin. 
As shown in Figure 2a, 2b, and Suppl Figure 2a, 2c, 
cerulenin significantly reduced the constitutive EGFR 
phosphorylation by reducing EGFR dimerization in the 
absence of serum. Furthermore, cerulenin also inhibited 
constitutive activation of ∆ECD-EGFR expressed in 
HEK293 cells (Figure 2c). To further determine the 
role of FASN in the intrinsic activation of EGFR, we 
overexpressed FASN in MCF10A cells (an EGFR positive 
noncancerous cell line) under serum free conditions, 
and found that phosphorylation of EGFR was increased 
with the increasing levels of FASN protein (Figure 2d). 
Consistent with this data, over expression of FASN in PC3 
(Figure 2e) and A549 cells (Suppl Figure 3) also increased 
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Figure 1: Constitutive activation of EGFR sustains cell proliferation in the absence of ligands. a. Serum starved PC3, 
DU145, A549 and HT-29 cells were tested for EGFR phosphorylation. b. PC3 and A549 cells grown in the absence of serum/ligands were 
tested for EGFR dimerization (crosslinked by DMP) and phosphorylation. Serum starved A549 and PC3 were treated with EGF +/− C225 
at 2.5 ug/ml c. or AEE788 at 2.5 uM d. for 15 minutes and measured for EGFR phosphorylation, EGFR and Actin using Western blot. 
e. Schematic diagram of WT and extra cellular domain deleted EGFR (∆ECD-EGFR). f. Western blot analysis of protein samples for 
pEGFR and EGFR (Flag) isolated from HEK 293 cells transfected with vector alone, WT EGFR or ∆ECD EGFR for 24 hours. g. Western 
blot analysis of protein samples for pAkt, Akt, pErk1/2, Erk1/2 and EGFR isolated from PC3 cells treated with EGF +/− AEE788 or EGF 
+/− C225 for 15 minutes similarly as cells used in c and d. h. A549 cells were treated with AEE788 or C225 for 5 days at the indicated 
concentrations and measured cell number. i. Colony formation assay on PC3 and A549 cells were treated with increasing concentrations 
of AEE788 or C225 as indicated in 6-well plate and colony formation was counted when the cells reached 80–90% confluence. Data are 
means of +/− SD of triplicates (Suppl Figure 1a and 1b). Asterisk indicates the statistical significance between treated group and DMSO 
(P-value ≤ 0.0001).
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Figure 2: Activation of EGFR by de novo fatty acid synthesis dependent palmitoylation. a. Western blot analysis of protein 
samples for pEGFR and EGFR isolated from PC3 cells treated with FASN inhibitor, cerulenin, at 5ug/ml for 8 hours. b. PC3 cells were 
treated with cerulenin for 8 hours and isolated protein samples were cross linked with BS3 as described in the materials and methods 
section. The cross linked samples were analyzed using Western blot for EGFR dimers. For control group, protein samples were left 
untreated. c. HEK 293 cells were transfected with ∆ECD EGFR for 24 hours followed by treatment with cerulenin in serum free medium 
for overnight before protein isolation and Western blot analysis. d. Western blot analysis of protein samples for pEGFR, EGFR and Actin 
isolated from MCF10A cells transfected with increasing FASN (Flag tagged) concentration for 24 hours followed by serum starvation for 
12 hours. e. Western blot analysis of protein samples (for indicated proteins) isolated from PC3 cells transfected with vector alone or FASN 
flag for 24 hours followed by serum starvation for 12 hours. f. Acyl-Biotin Exchange assay (ABE) for EGFR palmitoylation. PC3 cells were 
transfected with vector alone or FASN (panel 2e) and isolated samples were subjected to ABE assay for EGFR palmitoylation. HAM stands 
for hydroxyl amine. ABE assay was performed as described in the methods. g. Western blotting analysis of protein samples for pEGFR, 
EGFR and actin isolated from PC3 cells treated with a palmitoylation inhibitor, 2-bromopalmitate (2-BP), at 8uM for 6–8 hours. h. PC3 
cells were treated with or without 2-BP for 8 hours and EGFR dimers were detected using cross linking agent, BS3, followed western 
blot analysis i. Western blotting of ABE assay samples for EGFR palmitoylation prepared from PC3 cells treated with DMSO or EGF 
(10 ng/ ml) for 20 minutes in the presence or absence of cerulenin (pretreated at 5 ug/ml for 8 hours) (left panel) or 2-BP (pretreated at 6uM 
for 8 hours) (right panel). j. EGF induced EGFR dimerization was tested in the presence of cerulenin or 2-BP (pretreated for overnight). 
Protein samples were prepared in the presence or absence of cross linking agent (BS3 at 3 mM) for Western blot analysis of EGFR. 
k.  Western blot analysis of protein samples for pEGFR, EGFR and Actin isolated from A549 cells treated with 5ng of EGF +/− Cerulenin 
(5 ug/ml) or 2-BP (8 uM) for 15 minutes.
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the activation of EGFR and its downstream pathways 
(Akt and ERK) in the absence of serum. These results 
indicate that FASN mediated de novo fatty acid synthesis 
participates in the ligand-independent constitutive 
activation of EGFR.
FASN-dependent protein palmitoylation is critically 
involved in regulating activity, stability and cellular 
distribution of membranous proteins [17, 20]. The 
functional interrelationship between EGFR and FASN 
led us to speculate that palmitoylation of EGFR might 
be involved in EGFR activation. To test whether EGFR 
is palmitoylated in the absence of serum, we utilized the 
in vitro Acyl-Biotin exchange (ABE) assay to determine 
the palmitoylation level of EGFR immunoprecipitated 
from PC3 cells. As shown in Figure 2f, we found that 
EGFR is indeed palmitoylated, which was significantly 
increased by overexpression of FASN. Protein 
palmitoylation is catalyzed by a class or enzymes of 
palmitoyl acyltransferase (PAT), which can be inhibited 
by an inhibitor, 2-bromopalmitate (2-BP) [21]. Treatment 
of PC3 and A549 cells with 2-BP resulted in inhibition 
of constitutive activation (Figure 2g and Suppl Figure 2b) 
and dimerization (Figure 2h and Suppl Figure 2d) of 
EGFR. In the presence and absence of EGF, inhibition of 
FASN or PAT significantly reduced the levels of EGFR 
palmitoylation (Figure 2i), dimerization (Figure 2j), and 
phosphorylation (Figure 2k, Suppl Figure 4). Together, 
these data suggest that FASN mediated palmitoylation 
of EGFR plays a critical role in ligand-independent and 
ligand-dependent activation of EGFR.
Plamitoyl acyltransferases (PATs) interact 
with EGFR and activate EGFR by increasing 
palmitoylation
Protein palmitoylation is catalyzed by a class of 
enzymes known as PATs, which transfer the palmitoyl 
group of palmitoyl-CoA to the SH group of cysteine 
residue of a target protein. There are 23 known PATs in 
human and rodents, and human and mouse PATs are highly 
homologous [22]. To further investigate the role of PATs 
in activating EGFR, we transiently overexpressed a panel 
of 23 known mouse PATs individually into A549 cells and 
determined their effects on EGFR activation under serum 
free conditions. As shown in Figure 3a, over-expression 
of PATs 1, 2 (>95% homologous with human PAT2), and 
21 (>95% homologous with human PAT21) significantly 
activated EGFR, and each of these PATs also activated 
ERK and Akt in the absence of serum (Figure 3b). 
Furthermore, we also performed co-immunoprecipitation 
assay to test whether these PATs can physically interact 
with EGFR. Co-immunoprecipitation from HEK 293 cells 
co-transfected with flag-tagged EGFR and the HA-tagged 
PATs showed that PATs 1, 2 and 21 could physically 
interact with EGFR (Figure 3c). We also tested whether 
these EGFR-interacting PATs would increase EGFR 
palmitoylation. As shown in Figure 3d, over-expression of 
these PATs in A549 cells increased EGFR palmitoylation. 
Together, these data suggest that PATs can activate EGFR 
in the absence of external ligands.
Cysteine 797 is conserved in kinase active 
ErbB members and is important for EGFR’s 
palmitoylation and constitutive activation
Palmitoylation of proteins is catalyzed by PATs 
to form thioester bond between the sulfhydryl group of 
cysteine residues and the carboxyl group of palmitate 
[23]. Program assisted prediction found that several 
cysteine residues in the intracellular region of EGFR 
could be palmitoylated (data not shown). We focused 
on Cysteine 797 in this study because it is conserved in 
all the kinase active members of EGFR family [EGFR, 
HER2 (Cysteine 805), and Her4 (Cysteine 803)], but not 
in the kinase inactive HER3 (Figure 4a). In HER3, the 
corresponding cysteine residue is substituted with serine. 
To study the role of C797 in EGFR palmitoylation and 
constitutive activity, we expressed wild type or C797G 
(Cysteine is substituted with Glycine) mutant of EGFR 
in HEK 293 cells. As shown in Figure 4b and 4c, C797G 
mutation significantly reduced palmitoylation and 
constitutive activity of the full length EGFR. Supportively, 
C797G mutation also blocked palmitoylation and 
activation of the ∆ECD-EGFR (Figure 4d and 4e). 
Because dimerization is a key step for EGFR activation, 
we determined whether the reduced activity of C797G 
mutant could be due to defect in dimerization. As shown 
in Figure 4f, under serum free conditions, WT EGFR 
transfected into HEK293 cells formed dimers; however, 
the C797G EGFR mutant failed to form dimers regardless 
of EGF (Figure 4f). Consistently, EGF failed to activate 
the C797G mutant (Figure 4g). Furthermore, mutating 
the conserved cysteine sites in the other EGFR kinase-
active members, HER2 and HER4, blocked their effects 
on activating ERK signaling in HEK293 cells (Figure 4h). 
These results suggest the C797 is crucial for EGFR’s 
palmitoylation, dimerization, and activation.
Inhibition of FASN or PATs regulates localization 
and protein levels of EGFR
Protein palmitoylation often leads to tethering 
proteins to the plasma membrane. To test the role 
of de novo fatty acid synthesis dependent EGFR 
palmitoylation in EGFR cellular localization, we treated 
PC3 cells with cerulenin or 2-BP, co-stained for EGFR 
and lysosomes, and determined EGFR localization using 
confocal microscope imaging. As shown in Figure 5a, 
EGFR is predominantly localized at the plasma membrane 
of the control cells, and both cerulenin and 2-BP treatment 
decreased EGFR levels at the plasma membrane and 
increased EGFR levels at lysosomes, suggesting that 
inhibition of this mechanism reduces plasma membranous 
EGFR and promotes its lysosomal translocation. 
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Supportively, cerulenin and 2-BP also reduced EGFR 
protein levels (Figure 5b). These results suggest that 
de novo fatty acid synthesis dependent palmitoylation 
plays a critical role in maintaining the protein levels and 
plasma membrane localization of EGFR.
Inhibition of FASN or PATs sensitized cancer 
cells to EGFR TKIs
Knowing that EGFR’s palmitoylation plays a critical 
role in its function, we sought to test whether inhibition 
of FASN or PATs activity can increase the sensitivity of 
cancer cells to EGFR tyrosine kinase inhibitors (EGFR 
TKI). We treated A549 and PC3 cells with increasing 
concentrations of EGFR TKI, Iressa, (1 uM to 10 uM) 
for 30 minutes in the presence or absence of cerulenin or 
2-BP (pretreated for 3 hours). In the presence of cerulenin 
or 2-BP, Iressa showed an increased efficacy in inhibiting 
EGFR phosphorylation at every concentration compared 
with that of control (Figure 6a–6d). Consistently, inhibition 
of FASN or PATs significantly increased the sensitivity 
of PC3 and A549 cells to the growth inhibitory effects of 
EGFR kinase inhibitors (Figure 6e and 6f). In addition to 
the growth inhibitory effects, cerulenin and 2-BP treatment 
increased the pro-apoptotic effects of AEE788 as evidenced 
by increased levels of cleaved PARP and caspase 3 
(Figure 6g). These results indicate that the de novo fatty 
acid synthesis dependent palmitoylation plays a critical role 
in maintenance of cancer cell survival under EGFR TKI 
treatment.
DISCUSSION
EGFR is overexpressed or overactive in most 
cancers of epithelial origin. Based on the understanding 
of the canonical EGFR activation pathways, ligand 
induced dimerization of the receptor and activation of 
the tyrosine kinase activity of the receptor, anti-EGFR 
therapeutics have been developed for cancer therapy: 
monoclonal antibodies that block EGFR from binding to 
Figure 3: PAT 1, 2 and 21 increases EGFR activation and palmitoylation. a. Screening of PAT enzymes for EGFR activation. 
A549 cells were transfected with individual PAT (HA-tagged) constructs for 24 hours followed by 12 hours of serum starvation. Isolated 
protein samples were tested for EGFR activation using pEGFR antibody. b. Western blot analysis of protein samples for pEGFR, EGFR, 
pAkt, Akt, pErk 1/2, Erk 1/2 and Actin isolated from A549 cells transfected with PAT plasmids 1, 2, 21 or vector alone for 24 hours 
followed by serum starvation for 12 hours. c. Western blot analysis of immunoprecipitated samples for HA and EGFR antibodies. HEK 293 
cells were transfected with EGFR-flag alone or in combination with indicated PATs as shown in the Figure 3c and PAT enzymes were 
immunoprecipitated with HA antibody. d. Western blotting analysis of palmitoylated EGFR from PC3 cells transfected with vector alone 
or PATs.
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its activating ligands and ATP mimicking small molecule 
inhibitors that compete with ATP for the binding of 
tyrosine kinase domain of EGFR. In the clinic, the current 
approaches of anti-EGFR therapies have been facing 
critical challenges of innate resistance [5–7, 24] and 
inevitable acquired resistance in EGFR-positive cancers 
[3, 25, 26]. A better understanding on the mechanism by 
which EGFR executes its oncogenic functions is needed 
to improve the therapeutic efficacy of EGFR targeted 
therapies. Our understanding of EGFR functions in 
cancer cells has expanded in recent years, e.g. from its 
function at the plasma membrane to the nucleus [27] and 
to the mitochondrion; [15, 28, 29] from its tyrosine kinase 
dependent functions to its tyrosine kinase independent 
functions; [30, 31] from its ligand-dependent functions to 
its ligand-independent function [8, 9].
In this study, we have identified that ligand-
independent constitutive activation of EGFR maintains 
the proliferative ability of cancer cells in the absence 
of external ligands, and de novo fatty acid synthesis 
Figure 4: C797 site is conserved in kinase active ErbB members and is important for constitutive activation and 
palmitoylation of EGFR. a. Comparison of palmitoylation site (C797) of EGFR with HER2, HER3 and HER4. b. Western blotting 
analysis for palmitoylated EGFR prepared from HEK293 cells transfected with EGFR WT or C797G mutant (Flag-tagged). c. C797G 
mutation blocks EGFR constitutive phosphorylation when expressed in HEK 293 cells. d. C797G mutation blocks palmitoylation of 
∆ECD EGFR in HEK 293 cells. e. C797G mutation blocks ∆ECD EGFR constitutive phosphorylation in HEK 293 cells. f. HEK 293 cells 
were transfected with WT or C797G EGFR for 24 hours and treated with DMSO or EGF at 10 ng/ml for 20 minutes and protein samples 
were analyzed for EGFR dimers using Western blotting under reducing or non-reducing conditions. g. The same samples from panel f were 
subjected to Western blot analysis. h. Western blot analysis for Flag, pErk 1/2, Erk 1/2 and GAPDH. Protein samples were prepared from 
HEK 293 cells transfected with WT or cysteine mutants of ErbB members.
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dependent palmitoylation of EGFR is required for both 
the ligand-independent constitutive activation and ligand-
dependent activation of EGFR. The novelty of this finding 
resides at the intracellular and ligand-independent nature 
of this EGFR activation pathway. This pathway may 
have potentially contributed to the resistance to anti-
EGFR therapeutics in the clinic. Palmitoylation induced 
dimerization of EGFR may offset the effect of anti-EGFR 
antibody, and enhanced de novo fatty acid synthesis that is 
common in cancers and associated with chemoresistance 
[14, 32, 33] may counteract the growth inhibitory effect 
of small molecule TKIs during the intervals of TKI 
administration. This possibility is supported by our data 
that inhibition of FASN or PATs significantly potentiated 
TKIs’ growth inhibitory and pro-apoptotic effect.
Protein palmitoylation, the thioester linkage of 
palmitate moieties to cysteine residues, plays important 
role in regulating protein translocation, stability, 
and function. A wide range of proteins undergoes 
palmitoylation modification catalyzed by palmitoyl 
acyltransferases (PATs) [34]. Palmitate is, a 16-carbon 
saturated fatty acid, synthesized by FASN. Previously, we 
have found that, independent of its kinase activity, EGFR 
interacts with FASN at the plasma membrane in cancer 
cells [15]. It has been shown that expression of FASN 
alone is sufficient to activate EGFR and HER2 [14]. 
Given that plasma membrane-associated FASN plays a 
critical role in regulating the function of membranous 
proteins through protein palmitoylation, [35] the 
regulation of EGFR by palmitoylation was expected. 
Figure 5: Inhibition of de novo fatty acid synthesis or palmitoylation alters EGFR cellular distribution and reduces 
total EGFR levels. a. Representative immuno fluorescent images of PC3 cells. PC3 cells were treated with DMSO or cerulenin at 
5 ug/ml for 24 hours and stained for EGFR (green), lysosomes (red) and nucleus (DAPI, blue). Images were taken using Olympus confocal 
microscope using 60x objective. Scale bar is 30um. b. Western blot analysis of protein samples for EGFR and Actin isolated from PC3 cells 
and A549 cells treated with FASN inhibitor, cerulenin at 5ug/ml or 2-BP (6 uM) for 24 hours.
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Figure 6: FASN or PAT inhibitor sensitizes cancer cells to EGFR TKIs. Western blot analysis of protein samples for pEGFR, 
EGFR and Actin isolated from A549 cells treated (30 minutes) with increasing concentrations of EGFR tyrosine kinase inhibitor in the 
presence or absence of cerulenin at 5 ug/ml a. or 2-BP at 8 uM b. The cells were pretreated with either cerulenin or 2-BP for 5 hours 
before the treatment with Iressa. Western blot analysis of protein samples for pEGFR, EGFR and Actin isolated from PC3 cells treated 
(30 minutes) with increasing concentrations of EGFR tyrosine kinase inhibitor in the presence or absence of cerulenin at 5 ug/ml c. or 2-BP 
at 8 uM d, e. MTS assay in PC3 cells treated with EGFR TKI alone or in combination with cerulenin or 2-BP for 48 hours. f. MTS assay in 
A549 cells treated with EGFR TKI alone or in combination with cerulenin or 2-BP for 48 hours. Data are means of +/− SD of triplicates. 
Asterisk indicates the statistical significance between treated group and DMSO (P-value ≤ 0.001). g. Western blotting analysis of protein 
samples for PARP cleavage, cleaved caspase 3 and actin.
Oncotarget35001www.impactjournals.com/oncotarget
Our observations that palmitoylation of EGFR is 
required for its dimerization and subsequent activation 
(Figures 2 and 4) are novel, which suggest that this 
mechanism plays a fundamental role in EGFR’s kinase-
dependent functions. The fundamentality of EGFR 
palmitoylation is further supported by the fact that 
the critical cysteine residue for EGFR palmitoylation, 
Cys797 of EGFR, is conserved among the kinase active 
members of EGFR family (EGFR, HER2, and HER4) 
and is substituted by a serine residue in HER3 that 
lacks kinase activity. The exact molecular mechanism 
by which de novo fatty acid synthesis enhances survival 
of cancer cells is not completely understood. Our data 
suggest that ligand-independent activation of EGFR by 
FASN-dependent protein palmitoylation might be a part 
of this mechanism.
Data from this study suggest that targeting EGFR’s 
palmitoylation might be a more effective approach for 
EGFR based therapies, however, to achieve more specific 
inhibition at EGFR’s palmitoylation, further studies are 
needed to define the molecular nature of the interplay 
among EGFR, FASN, and PATs.
MATERIALS AND METHODS
Reagents and cell lines
In this study we used two prostate cancer cell lines 
(PC3, DU145), lung cancer cell line (A549) colon cancer 
cell line (HT29), and non-cancer cell lines (MCF10A 
and HEK293T). All of the cancer cells were cultured 
in DMEM supplemented with 10% fetal bovine serum 
(FBS), 1% antibiotics, 5.5 mM glucose and non-cancer 
cells were grown in DMEM with 25 mM glucose. FASN 
inhibitor (Cerulenin, cat # C2389) and 2-Bromo palmitate 
(cat # 21604) were purchased from Sigma Aldrich. EGFR 
inhibitors AEE788 (Cat# S1486), Iressa (Cat #S1025), 
Erlotinib (Cat #S7786) and AG1478 (Cat  # S2728) 
were purchased from Selleck Bio. Antibodies for FASN 
(cat # sc-55580), EGFR (Cat # sc-03), beta actin (Cat # 
sc-1616) and Tubulin (Cat # sc-5286) were purchased 
from Santa Cruz Biotechnology. EGFR monoclonal 
antibody, C225 (Cat #MABF120), was from EMD 
Millipore for EGFR immuno precipitation studies. 
Anti-EGFR for immuno staining (Cat #4267), Akt, 
pAkt, Erk1/2 (cat #9102) and pErk1/2 (Cat #9101) were 
obtained from Cell Signaling. Anti-flag (M2) antibody 
(Cat # F3165) was from Sigma Aldrich. Anti-pEGFR 
(Y1137) (Cat # 44794G) antibody was from Invitrogen. 
Lysotracker Red (Cat #L-7528) was purchased from life 
technologies.
Cloning and mutagenesis
EGFR, HER2 and HER4 were PCR amplified 
from PCDNA3.1 constructs and sub cloned into 
pRK5F (flag-tag) vector. Specific cysteine mutations 
on EGFR constructs were created using Stratagene 
Quickchange Lightening site directed mutagenesis 
kit purchased from Agilent technologies (Santa 
Clara, CA). Primers for EGFR C797G mutation are 
“CGCAGCTCATGCCCTTCGGCGGCCTCCTGGAC 
TATGTCCGG (Forward) and 
CCGGACATAGTCCAGGAGGCCGCCGAAGGGCA 
TGAGCTGCG (reverse). Primers 
for HER2 C805G mutation are 
“GCTTATGCCCTATGGCAGCCTCTTAGACCATG 
TCCGG” (forward) and 
CCGGACATGGTCTAAGAGGCTGCCATAGGGCA 
TAAGC (reverse). Primers for HER4 C803G are 
CTTATGCCCCATGGCGGCCTGTTGGAGTATGTCC 
(forward) and 
GGACATACTCCAACAGGCCGCCATGGGGCATAAG 
(reverse). The HA-tagged PAT expression plasmids [36] 
were obtained from Dr. Masaki Fukata at the National 
Institutes of Natural Sciences, Okazaki, Japan, as a gift.
Transfection and western blotting
Plasmid transfections were performed using 
lipofectamine 2000 according to the manufacturer 
instructions. Protein samples were prepared by lysing 
the cells in RIPA buffer (Cat # R0278, Sigma Aldrich) 
supplemented with protease inhibitors and phosphatase 
inhibitors on ice for 30 minutes. Lysed cell lysates were 
collected and centrifuged at 14000 rpm for 15 minutes at 
4°C. Equal amount of proteins were subjected to the SDS 
PAGE and western blotting analysis for proteins of interest 
using antibodies at optimized concentrations.
Immunoprecipitation and immunostaining
Equal amount (500 ug) of protein samples were 
added to the eppendorf tube containing 25ul of protein 
A/G beads and 1ug of antibody and incubated at 4°C for 
overnight on a shaker. After overnight incubation, the 
beads were washed with 600ul of RIPA buffer for three 
times. Immunoprecipitated proteins were eluted directly 
into lamellae buffer and boiled for 5 minutes and subjected 
to western blotting. Immunocytochemistry (ICC) was 
performed as described by previously.
EGFR dimerization assay
EGFR dimers were detected through western 
blotting analysis using non-reducing conditions 
(Bollu et al 2014) and cross linking agents (BS3 and 
DMP). After treatments with drugs, cells were washed 
with PBS and incubated with 3 mM BS3 (Cat # 21580, 
Thermoscientific) or DMP (Cat # D8388, Sigma Aldrich) 
at 12 mg/ml for one hour on shaker at 4C. Reaction was 
quenched by adding 250 mM glycine (for BS3 method) 
or 50 mM ethanolamine (for DMP method) for 5 minutes 
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at 4C. Cells were washed with ice cold PBS and lysed 
with RIPA buffer.
In vitro palmitoylation assay
The Acyl-Biotin exchange palmitoylation assay 
was carried out according the protocol used by others. 
EGFR was immuno precipitated from protein samples 
using 1 ug of EGFR monoclonal antibody, C225. To block 
non-palmitoylated cysteine residues, immuno precipitated 
EGFR was treated with 50 mM NEM in RIPA buffer at 
4°C for 2 hours on a shaker followed by three washes with 
RIPA buffer. EGFR was then treated with hydroxylamine 
(HAM) buffer to remove palmitate from Cysteine residues 
(1 M Hydroxylamine, 50 mM tris, 150 mM Nacl, 5 mM 
EDTA, 0.2% TX100, pH 7.4) at room temperature for 
2 hrs on a shaker. For mock, EGFR was treated with same 
buffer without hydroxyl amine. EGFR was then treated 
with 4 uM of BMCC-Biotin in 50 mM tris, 150 mM Nacl, 
5 mM EDTA, 0.2% TX100, pH 6.2 for 1–2 hours followed 
by three washes to remove excess biotin. 60 ul of reducing 
protein sample buffer was added and samples were boiled 
for two minutes to elute EGFR from beads. 20% of sample 
was loaded on to SDS PAGE gel. Membrane was blocked 
with 5% BSA for overnight followed by incubation 
with streptavidin conjugated with HRP at 1:30000 for 
60 minutes and Biotin-streptavidin HRP complexes were 
visualized by exposing the membrane to ECL and then to 
X-ray film.
Cell proliferation assay
Seven day cell proliferation assays were carried out 
in 96-well plates by measuring the cellular DNA content 
using a FluoReporter Blue fluorometric double-stranded 
DNA Quantitation kit (Life Technologies cat#: f-2962) 
following the manufacturer’s protocol. Florescence was 
measured at 360 nm excitation and 460 nm emission.
Colony formation assay
1000–2000 cells were plated in each well of 
6-well plates and grown in DMEM supplemented with 
5% charcoal stripped serum for 24 hours followed 
by treatment with indicated concentrations of drugs. 
Medium was changed every 72 hours until the control 
cells reached 80–90% confluence. At the end of the 
experiment, the cells were fixed with 4% PFA and stained 
with 2.5% crystal violet for 10 minutes. Images were 
taken using a scanner.
MTS assay
Cell viability assay was performed using a MTS 
assay kit (Cat # G3582, Promega) following manufacturer 
instructions in 96 well plates.
Statistics
Student two-tailed t-test was used to compare the 
values (mean ± SD) of triplicate control and experimental 
groups of three independent experiments. P < 0.05 is 
considered as significant difference.
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